Skip to main content
Top
Published in: Journal of Gastroenterology 3/2020

Open Access 01-03-2020 | Hepatitis B | Original Article—Liver, Pancreas, and Biliary Tract

Transition in the etiology of liver cirrhosis in Japan: a nationwide survey

Authors: Hirayuki Enomoto, Yoshiyuki Ueno, Yoichi Hiasa, Hiroki Nishikawa, Shuhei Hige, Yasuhiro Takikawa, Makiko Taniai, Toru Ishikawa, Kohichiroh Yasui, Akinobu Takaki, Koichi Takaguchi, Akio Ido, Masayuki Kurosaki, Tatsuya Kanto, Shuhei Nishiguchi, Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH

Published in: Journal of Gastroenterology | Issue 3/2020

Login to get access

Abstract

Background

To assess the recent real-world changes in the etiologies of liver cirrhosis (LC) in Japan, we conducted a nationwide survey in the annual meeting of the Japan Society of Hepatology (JSH).

Methods

We investigated the etiologies of LC patients accumulated from 68 participants in 79 institutions (N = 48,621). We next assessed changing trends in the etiologies of LC by analyzing cases in which the year of diagnosis was available (N = 45,834). We further evaluated the transition in the real number of newly identified LC patients by assessing data from 36 hospitals with complete datasets for 2008–2016 (N = 18,358).

Results

In the overall data, HCV infection (48.2%) was the leading cause of LC in Japan, and HBV infection (11.5%) was the third-most common cause. Regarding the transition in the etiologies of LC, the contribution of viral hepatitis-related LC dropped from 73.4 to 49.7%. Among the non-viral etiologies, alcoholic-related disease (ALD) and nonalcoholic steatohepatitis (NASH)-related LC showed a notable increase (from 13.7 to 24.9% and from 2.0 to 9.1%, respectively). Regarding the real numbers of newly diagnosed patients from 2008 to 2016, the numbers of patients with viral hepatitis-related LC decreased, while the numbers of patients with non-viral LC increased.

Conclusions

HCV has remained the main cause of LC in Japan; however, the contribution of viral hepatitis as an etiology of LC is suggested to have been decreasing. In addition, non-viral LC, such as ALD-related LC and NASH-related LC, is suggested to have increased as etiologies of LC in Japan.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Ward JW, Hinman AR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats? Gastroenterology. 2019;156:297–310.CrossRef Ward JW, Hinman AR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats? Gastroenterology. 2019;156:297–310.CrossRef
4.
go back to reference Rosen HR, Ghany MG, Chung RT, et al. NAM 2017 Report: a national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD’s response. Hepatology. 2017;66:1020–2.CrossRef Rosen HR, Ghany MG, Chung RT, et al. NAM 2017 Report: a national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD’s response. Hepatology. 2017;66:1020–2.CrossRef
5.
go back to reference Oza N, Isoda H, Ono T, Kanto T. Current activities and future directions of comprehensive hepatitis control measures in Japan: the supportive role of the Hepatitis Information Center in building a solid foundation. Hepatol Res. 2017;47:487–96.CrossRef Oza N, Isoda H, Ono T, Kanto T. Current activities and future directions of comprehensive hepatitis control measures in Japan: the supportive role of the Hepatitis Information Center in building a solid foundation. Hepatol Res. 2017;47:487–96.CrossRef
6.
go back to reference Tsuji K, Kurosaki M, Itakura J, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018;53:1142–50.CrossRef Tsuji K, Kurosaki M, Itakura J, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018;53:1142–50.CrossRef
8.
go back to reference Naganuma A, Chayama K, Notsumata K, et al. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol. 2019;54:752–61.CrossRef Naganuma A, Chayama K, Notsumata K, et al. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol. 2019;54:752–61.CrossRef
9.
go back to reference Tanaka K, Takahashi H, Hyogo H, et al. Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease. Hepatol Res. 2019;49:296–303.CrossRef Tanaka K, Takahashi H, Hyogo H, et al. Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease. Hepatol Res. 2019;49:296–303.CrossRef
10.
go back to reference Yoneda M, Imajo K, Takahashi H, et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol. 2018;53:181–96.CrossRef Yoneda M, Imajo K, Takahashi H, et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol. 2018;53:181–96.CrossRef
13.
go back to reference Michitaka K, Nishiguchi S, Aoyagi Y, et al. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2010;45:86–94.CrossRef Michitaka K, Nishiguchi S, Aoyagi Y, et al. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2010;45:86–94.CrossRef
14.
go back to reference Suzuki Y, Ohtake T, Nishiguchi S, et al. Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res. 2013;43:1020–31.PubMed Suzuki Y, Ohtake T, Nishiguchi S, et al. Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res. 2013;43:1020–31.PubMed
15.
go back to reference The Japan Society of Hepatology. Clinical guidelines for management of chronic hepatitis and cirrhosis 2016. Tokyo: Bun-kodo; 2016. The Japan Society of Hepatology. Clinical guidelines for management of chronic hepatitis and cirrhosis 2016. Tokyo: Bun-kodo; 2016.
16.
go back to reference Textbook of Hepatology. 2nd Edition. Tokyo: Nankodo; 2016. Textbook of Hepatology. 2nd Edition. Tokyo: Nankodo; 2016.
17.
go back to reference Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54:367–76.CrossRef Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54:367–76.CrossRef
18.
go back to reference Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res. 2015;45:59–74.CrossRef Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res. 2015;45:59–74.CrossRef
19.
go back to reference Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17:748–55.CrossRef Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17:748–55.CrossRef
20.
go back to reference Wang X, Lin SX, Tao J, et al. Study of liver cirrhosis over ten consecutive years in Southern China. World J Gastroenterol. 2014;20:13546–55.CrossRef Wang X, Lin SX, Tao J, et al. Study of liver cirrhosis over ten consecutive years in Southern China. World J Gastroenterol. 2014;20:13546–55.CrossRef
21.
go back to reference Kang JH, Matsui T. Changing etiology in liver cirrhosis in sapporo Japan. Euroasian J Hepatogastroenterol. 2018;8:77–80.CrossRef Kang JH, Matsui T. Changing etiology in liver cirrhosis in sapporo Japan. Euroasian J Hepatogastroenterol. 2018;8:77–80.CrossRef
22.
go back to reference Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in foreseeable future. Oncology. 2002;62(Suppl1):8–17.CrossRef Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in foreseeable future. Oncology. 2002;62(Suppl1):8–17.CrossRef
23.
go back to reference Mizuno K, Toyoda H, Yasuda S, et al. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. J Gastroenterol. 2019;54:829–36.CrossRef Mizuno K, Toyoda H, Yasuda S, et al. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. J Gastroenterol. 2019;54:829–36.CrossRef
Metadata
Title
Transition in the etiology of liver cirrhosis in Japan: a nationwide survey
Authors
Hirayuki Enomoto
Yoshiyuki Ueno
Yoichi Hiasa
Hiroki Nishikawa
Shuhei Hige
Yasuhiro Takikawa
Makiko Taniai
Toru Ishikawa
Kohichiroh Yasui
Akinobu Takaki
Koichi Takaguchi
Akio Ido
Masayuki Kurosaki
Tatsuya Kanto
Shuhei Nishiguchi
Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH
Publication date
01-03-2020
Publisher
Springer Singapore
Published in
Journal of Gastroenterology / Issue 3/2020
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01645-y

Other articles of this Issue 3/2020

Journal of Gastroenterology 3/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.